Progression-free and overall survival data from Companion-002 are due this quarter.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
Tough equity markets as well as competitor developments prompt a narrowed focus.
Giredestrant will soon become the first oral SERD to yield first-line data.
The company hits an FDA-mandated enrolment target, but only in follicular lymphoma.
But this adds another complexity, and has camizestrant really scored a first-line win?
The company is starting a phase 3 trial of sacituzumab tirumotecan in first-line TNBC.
The Met x Met ADC REGN5093-M114 has been discontinued, but a Met x Met bispecific antibody remains.
